Total: $59.1 million

Top drug
Advair (COPD): $47.7 million
Watch the TV commercial here >>

GlaxoSmithKline ($GSK) put its advertising dollars to work generating sales of asthma treatment Advair. It was its top-selling drug at $7.7 billion last year, making up about 20% of the company's sales. The respiratory drug actually went off patent in 2010, but its Diskus inhaler is so difficult to copy that no generics have challenged it and none are on the horizon. That is despite an FDA decision to limit the clinical testing required for approval. Teva Pharmaceutical Industries ($TEVA), the largest generic drugmaker in the world, said that even with the new ground rules, it doesn't expect to see true substitutes for the GSK best-seller before 2018. U.S. sales of Advair in the first 6 months of the year were up 5% to $3.6 billion.


Suggested Articles

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.